2nd Quarter - Report

THE MCMANUS GROUP for DENDREON PHARMACEUTICALS LLC

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Access to autologous cellular immunotherapies in Medicare Part B. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022.

Foreign entity interest: Dendreon is a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.

LobbyistCovered position, as disclosed
JOHN MCMANUS LA, Bill Thomas. Staff Director, W&M Health Subcommittee

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Support for S. 297/H.R. 1300 - PSA Screening for HIM Act.

Foreign entity interest: Dendreon is a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.

LobbyistCovered position, as disclosed
JOHN MCMANUS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 297 (119th), H.R. 1300 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.